Find Candesartan Cilexetil Hydrochlorothiazide (Atacand HCT) combination generic drug prices and manufacturer details. Prices may vary by chemist. Click your brand name for cost information.

Candesartan Cilexetil and Hydrochlorothiazide generic contains angiotensin II receptor antagonist and thiazide diuretic, ... You'll also find brand names used in india and internationally, ...

Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $21.2 billion in annual brand sales, for the 12 months ending June 30, 2012, according to IMS Health.

Candesartan cilexetil, hydrochlorothiazide; 16mg/12.5mg, 32mg/12.5mg, 32mg/25mg; scored tabs. Not for initial therapy. May be substituted for titrated components. BP not controlled on HCTZ 25mg ...

The total value of all payments for the Atacand brand is $400m AstraZeneca has completed the divestment of the rights to its heart failure and hypertension brand Atacand (candesartan cilexetil) in ...

Mylan announced that the FDA has approved its abbreviated new drug application (ANDA) for Candesartan Cilexetil and Hydrochlorothiazide Tablets, the generic version of AstraZeneca's Atacand HCT.

Wayne, PA - The FDA has approved a new antihypertensive, Atacand HCT?, a combination of the angiotensin II receptor blocker candesartan cilexetil (Atacand®) and the diuretic hydrochlorothiazide ...

Candesartan cilexetil lowers blood pressure in a dose-dependent manner (at doses of up to 32 mg). [49,50,51] The 16- and 32-mg daily doses seem to be more effective than lower doses (4 and 8 mg ...

Canonsburg-based generic drug maker Mylan Inc. (Nasdaq:MYL) on Wednesday announced that it has received 180-day marketing exclusivity for certain strengths of candesartan cilexetil and ...

Blood pressure in SHR-SP. In SHR-SP, the SBPs before the administration of placebo, candesartan, candesartan plusamlodipine and candesartan plus HCTZ were 181±5.1, 181±4.4, 182±2.7 and 182±2.7 ...

The initial analysis focused on the comparison of candesartan and losartan in all the trials identified, including those employing a fixed-dose combination of the two drugs with HCTZ.